(VIANEWS) – Shares of OXURION (BEL 20: OXUR.BR) jumped by a staggering 31.58% in 5 sessions from €0.01 to €0.01 at 17:22 EST on Thursday, after five consecutive sessions in a row of losses. BEL 20 is falling 0.51% to €3,776.32, after two consecutive sessions in a row of losses.
OXURION’s last close was €0.00, 99.61% below its 52-week high of €1.20.
About OXURION
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist, which is in Phase II clinical trials for the treatment of DME. Oxurion NV has collaboration agreements with Bicycle Therapeutics and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Earnings Per Share
As for profitability, OXURION has a trailing twelve months EPS of €-0.732.
Moving Average
OXURION’s worth is way under its 50-day moving average of €0.01 and way below its 200-day moving average of €0.09.
Revenue Growth
Year-on-year quarterly revenue growth declined by 57.9%, now sitting on 595k for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, OXURION’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for OXURION is 13802409 which is 91.55% below its average volume of 26586700.
More news about OXURION (OXUR.BR).
